z-logo
Premium
Combined tetrahydrocannabinol and cannabidiol to treat pain in epidermolysis bullosa: a report of three cases
Author(s) -
Schräder N.H.B.,
Duipmans J.C.,
Molenbuur B.,
Wolff A.P.,
Jonkman M.F.
Publication year - 2019
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.17341
Subject(s) - cannabidiol , medicine , epidermolysis bullosa , analgesic , tetrahydrocannabinol , cannabinoid , opioid , dermatology , anesthesia , cannabis , psychiatry , receptor
Summary Epidermolysis bullosa ( EB ) is a genetic blistering disorder characterized by intense pain related to disease pathology and care‐based interventions. Opioid‐based therapies underpin pain care in EB ; however, they are unable to provide adequate analgesia in a significant proportion of patients. Cannabinoid‐based medicines ( CBM s) have been studied increasingly for pain conditions of various aetiologies and pose as a novel dimension for pain care in EB . We present three patients with EB who were prescribed pharmaceutical‐grade sublingually administered CBM s comprising tetrahydrocannabinol and cannabidiol. All three patients reported improved pain scores, reduced pruritus and reduction in overall analgesic drug intake.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here